Diet, Gut Microbiota and NAFLD
Diet is considered as one of the main drivers to modulate the composition of gut microbiota, which participate in different processes, affecting human metabolism. A disruption in the homeostasis...
NASH Observatory
⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.
Read MoreDiet, Gut Microbiota and NAFLD
The role of PPARs in NASH fibrogenesis
Prof Gyongyi Szabo, USA discusses the role of PPARs in NASH fibrogenesis. This video was filmed in Boston during the Liver meeting 2019.
HbA1c at normal-range levels and NAFLD
Longitudinal observations were performed by C. Chen et al. in a cohort of 2,811 participants with no liver disease at inception. The rate of the conversion to NAFLD was 15.7%, with a steady increase in prevalence...
The Role of PPARs in Inflammation
Prof Frank Tacke, Germany, discusses the role of PPARs in adipose tissue and liver inflammation. This video was filmed in Boston during the Liver meeting 2019.
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Well-established drugs that are indicated for the treatment of type 2 diabetes and hyperlipidemia are thought to exert effects that alleviate the pathological features of NASH. One class of these drugs targets peroxisome...
DNA Hydroxymethylation at the Interface of the Environment and Nonalcoholic Fatty Liver Disease.
NAFLD is a multi-faceted disease with metabolic, genetic, epigenetic, and environmental determinants. An increasing number of studies has also provided evidence for the role of xenobiotics in the genesis of steatosis...
Evaluation of Dietary Approaches for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review.
The optimal nutritional approach to treat NAFLD remains unclear. N. Saeed et al. (Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor) conducted a systematic...
Important trials during the Liver meeting in Boston
Prof Sven Francque, Belgium discusses the value of the clinical trials results presented in Boston during the Liver meeting 2019.
Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease.
Silvia Sookoian et al. (Institute of Medical Research A Lanari, University of Buenos Aires Faculty of Medicine, Buenos Aires, Argentina) aimed to characterise the liver tissue bacterial metataxonomic signature in two independent...
Prof Jordi Gracia-Sancho, Barcelona, discusses the need to develop new therapeutic approaches that target more than one molecular pathway for chronic liver disease.
For me, one of the key take home messages of…
Does SEN-V and other non-A-E hepatotropic viruses contribute to the development and progression of non-alcoholic fatty liver disease?
Approximately 10-20% of patients with non-alcoholic fatty liver disease (NAFLD) are at risk of progressing to cirrhosis. The cause of such progression is unclear. SEN-V is a hepatotropic virus that has been associated with more severe...
Small but mighty: Platelets in NASH and other chronic liver diseases.
Several pleiotropic effects of platelets on liver homeostasis and disease have been identified in recent studies. These effects are distinct from their long-recognized roles in hemostasis and coagulation. Recent evidence...